Sanofi And Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection For Preferred Access
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Dec. 11, 2015 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that UnitedHealth Group will provide preferred access to Praluent® (alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, Medicare, and Managed Medicaid patients. Praluent is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies ... Read News
No comments:
Post a Comment